NCT01514461View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Familial Chylomicronemia Syndrome (FCS)
Interventions
DRUG

LCQ908

LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

DRUG

Placebo

LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

Trial Locations (14)

7925

Novartis Investigative Site, Cape Town

20246

Novartis Investigative Site, Hamburg

29010

Novartis Investigative Site, Málaga

41013

Novartis Investigative Site, Seville

44093

Novartis Investigative Site, Nantes

50937

Novartis Investigative Site, Cologne

69677

Novartis Investigative Site, Bron

75651

Novartis Investigative Site, Paris

98104

Novartis Investigative Site, Seatlle

G7H 7P2

Novartis Investigative Site, Chicoutimi

G1V4M6

Novartis Investigative Site, Ste-Foy

H2W1R7

Novartis Investigative Site, Ouest-Montreal

1105 AZ

Novartis Investigative Site, Meibergdreef 9

M13 9NT

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY